Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05672745 · ClinicalTrials.gov registry record · NA

How Phenotypical Characteristics of Woebot Users Are Related to Clinical Outcomes

A NA study, sponsored by Woebot Health.

Completed
Registry status
NA
Development phase
256
Enrollment target

NCT05672745: Completed NA study, sponsored by Woebot Health.

NCT05672745 is a NA study that has completed, run by Woebot Health. The registered enrollment target is 256 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05672745, a NA study, has completed, sponsored by Woebot Health.

COMPLETED
Registry status
NA
Development phase
256 participants
Enrollment target

Study Summary

The goal of this observational study is to understand the characteristics of Woebot users as they relate to clinical outcomes. The objectives it aims to address are: 1. To assess Woebot usage patterns, satisfaction ratings, self-efficacy, stress, resilience, work productivity and activity impairment, alexthymia, and bond over time based on demographic, clinical baseline levels, and attitudinal characteristics 2. Among users who present with clinical levels of anxiety or depression, to assess the contribution of demographic characteristics, attitudinal characteristics, and patterns of engagement on clinical outcomes of interest over time 3. To collect and explore attitudinal characteristics of Woebot users regarding their experiences with mental health care and perceived value of digital tools for emotional support 4. Explore meaningful subgroups of Woebot users based on demographic and attitudinal characteristics, clinical outcomes, and patterns of engagement Participants who meet study eligibility requirements will be: * invited to engage with the Woebot Life program for 8 weeks * complete survey assessments at day 3, week 4 (mid-intervention), and week 8 (end of intervention)

Primary Outcome

Data tracking mobile application use, including conversational interactions with Woebot and patterns of engagement over time, will be collected throughout the duration of treatment (8-weeks).

Interventions

  • DEVICE WB-LIFE

Trial Details

FieldValue
Enrollment Target 256 participants
Start Date 2022-05-11
Est. Completion 2022-07-23
Phase NA
Woebot Health

13 total trials

What the finished NCT05672745 record still lists

NCT05672745 is an interventional study that assigns participants to a tested intervention. The registered 256 participants enrollment target is mid-sized for trials with a published cap, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (82% lower).

The record links to 0 conditions, and to 1 intervention - of which WB-LIFE is the first listed.

NCT05672745 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT05672745 about?

NCT05672745 is a clinical study titled "How Phenotypical Characteristics of Woebot Users Are Related to Clinical Outcomes". The goal of this observational study is to understand the characteristics of Woebot users as they relate to clinical outcomes. The objectives it aims to address are: 1. To assess Woebot usage patterns, satisfaction ratings, self-efficacy, stress, resilience, work productivity and activity impairme...

What is the current status of trial NCT05672745?

This trial is currently completed. It is a NA study. The enrollment target is 256 participants. The study started on 2022-05-11. Estimated completion is 2022-07-23.

What interventions are being tested in trial NCT05672745?

The interventions under investigation include: WB-LIFE (DEVICE).

Who is sponsoring clinical trial NCT05672745?

This trial is sponsored by Woebot Health, which has 13 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT05672745's enrollment target sits among peer trials

256 404th of 2000 higher than 1,594 of 2,000 other NA trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02464696 · 256 participants · NA

    Non-invasive Ventilation in Reducing the Need for Intubation in Patients With Cancer and Respiratory Failure

  • NCT03793062 · 256 participants

    Genetic and Epigenetic Basis of Chronic Wounds

  • NCT04322318 · 256 participants · Phase 2

    A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT

  • NCT04468360 · 256 participants · Phase 2

    Facilitation of Extinction Retention and Reconsolidation Blockade in PTSD

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT05672745, the US trial registry maintained by the National Library of Medicine. NCT05672745 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.